Literature DB >> 6143752

Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).

M S Lui, M A Faderan, J J Liepnieks, Y Natsumeda, E Olah, H N Jayaram, G Weber.   

Abstract

Tiazofurin, a C-nucleoside, was cytotoxic in hepatoma 3924A cells grown in culture with an LC50 = 7.5 microM. In the culture, a closely linked dose-related response of tumor cell-kill and depletion of GTP pools was observed after tiazofurin treatment. In rats carrying subcutaneously transplanted hepatoma 3924A solid tumors, a single intraperitoneal injection of tiazofurin (200 mg/kg) caused a rapid inhibition of IMP dehydrogenase (EC 1.2.1.14) activity and depleted GDP, GTP, and dGTP pools in the tumor; concurrently, the 5-phosphoribosyl 1-pyrophosphate (PRPP) and IMP pools expanded 8- and 15-fold, respectively. Tiazofurin decreased tumoral IMP dehydrogenase activity and dGTP pools in a dose-dependent manner over a range of 50-200 mg/kg; by contrast, the depletion of GTP and the accumulation of IMP and PRPP pools were near maximum at 50 mg/kg. The increase in PRPP pools may be attributed to an inhibition by IMP of the activity of hypoxanthine-guanine phosphoribosyltransferase (EC 2.4.2.8). The IMP dehydrogenase activity and the pools of ribonucleotides returned to the normal range by 24-48 h after the single injection of tiazofurin. However, the markedly depleted dGTP pools remained low for 72 h. Tiazofurin treatment resulted in significant anti-tumor activity in rats inoculated with hepatoma 3924A. The decrease in GTP levels and particularly the sustained depletion in the dGTP pools may explain, in part at least, the chemo-therapeutic action of tiazofurin on hepatoma 3924A. This is the first report showing that a marked therapeutic response was achieved against rapidly growing hepatoma 3924A by treatment with a single anti-metabolite.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143752

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Oncolytic activity and mechanism of action of a novel L-cysteine derivative, L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride.

Authors:  H N Jayaram; M S Lui; J Plowman; K Pillwein; M A Reardon; W L Elliott; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.

Authors:  E Olah; Y Natsumeda; T Ikegami; Z Kote; M Horanyi; J Szelenyi; E Paulik; T Kremmer; S R Hollan; J Sugar
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Small elevations of glucose concentration redirect and amplify the synthesis of guanosine 5'-triphosphate in rat islets.

Authors:  S A Metz; M Meredith; M E Rabaglia; A Kowluru
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

4.  Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  J A Maroun; D J Stewart
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

Review 5.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

Review 6.  Role of differentiation induction in action of purine antimetabolites.

Authors:  G Weber; Y Hata; N Prajda
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion.

Authors:  G Batist; R W Klecker; H N Jayaram; J F Jenkins; J Grygiel; D C Ihde; J L Eddy; R L Fine; I G Kerr; J M Collins
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

Authors:  K Pillwein; H N Jayaram; G Weber
Journal:  Blut       Date:  1988-08

9.  Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.

Authors:  H N Jayaram; K Murayama; K Pillwein; W Zhen; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  R M Green; D J Stewart; J A Maroun
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.